Customized Solutions for Nephrectomy Model Development
Download
Chronic kidney disease (CKD) is characterized by progressive renal function loss lasting over three months. As disease progression leads to glomerulosclerosis and tubulointerstitial fibrosis, the 5/6 nephrectomy (remnant kidney) model serves as a gold-standard surgical platform. By resecting ~83% of total renal mass, this model triggers hyperfiltration injury, hemodynamic changes, and progressive functional decline, making it an indispensable tool for mechanistic studies and novel therapy evaluation.
At Protheragen, we offer comprehensive, end-to-end preclinical research services spanning diagnostics development, therapeutic development, disease model development, and preclinical research. To support renal drug discovery and translational research, we provide custom 5/6 nephrectomy model development services across multiple species—simulating the pathological features and progression of human CKD with exceptional precision and reproducibility.
Overview of 5/6 Nephrectomy Animal Models
The 5/6 nephrectomy animal model simulates progressive chronic renal failure through surgical reduction of five-sixths of total renal mass. This reduction forces residual nephrons to undergo severe hyperfiltration, hyperperfusion, and compensatory hypertrophy. Over time, these hemodynamic alterations trigger a hallmark cascade of pathological events, including glomerulosclerosis, tubulointerstitial fibrosis, renal vascular remodeling, elevated serum urea/creatinine, severe proteinuria, and secondary complications such as renal anemia and renovascular hypertension. Protheragen utilizes optimized multi-step surgical protocols and refined microsurgical platforms to ensure minimal perioperative mortality and highly consistent disease phenotypes.
Applications of 5/6 Nephrectomy Animal Models
The 5/6 nephrectomy model is a versatile experimental tool widely utilized across various stages of translational renal research and drug discovery:
Drug Efficacy & Therapeutic Screening
Evaluating the renoprotective, anti-fibrotic, and anti-inflammatory properties of candidate compounds (e.g., ACEi/ARBs, SGLT2 inhibitors) by assessing parameters such as creatinine clearance, proteinuria reduction, and histological preservation.
Elucidation of CKD Pathopathways
Investigating fundamental biological mechanisms underlying progressive renal failure, including renal hemodynamic changes, oxidative stress signaling, extracellular matrix remodeling, and pro-fibrotic pathways.
Systemic Complication Research
Serving as a pathophysiological model to study secondary CKD manifestations, such as renovascular hypertension, renal anemia, vascular calcification, and chronic kidney disease-mineral and bone disorder (CKD-MBD).
Multi-Species Translational Validation
Enabling cross-species efficacy and safety evaluation—from rodent proof-of-concept studies (mouse/rat) to larger non-rodent model testing (rabbit)—to de-risk clinical candidate selection.
Workflow for 5/6 Nephrectomy Animal Model Development
We follow a standardized, highly controlled multi-step workflow to guarantee model quality, high survival rates, and robust statistical reliability:
- Acclimation & Baseline Assessment: Animal housing in SPF-certified environments and pre-procedural baseline monitoring (body weight, baseline blood, and urine parameters).
- First-Stage Surgery: Precision microsurgery under strict anesthesia to resect or electrocoagulate ~2/3 of the left renal parenchyma (upper and lower poles).
- Recovery Period & Perioperative Care: Standardized analgesia and intensive post-operative care over a 7-day recovery phase.
- Second-Stage Surgery: Complete surgical excision of the contralateral right kidney 7 days after the primary surgery to achieve total 5/6 mass reduction.
- In Vivo Monitoring & End-Point Analysis: Longitudinal tracking of physiological/biochemical parameters (BUN, creatinine, proteinuria, blood pressure) followed by comprehensive histopathological (H&E, Masson, PAS) and biomarker evaluations.
Integrated Preclinical Research Services for Chronic Kidney Disease (CKD)
Protheragen provides one-stop preclinical research solutions covering the complete CKD drug development lifecycle—from early-stage discovery and candidate validation to full IND-enabling study packages. Our specialized service offerings include:
Diagnostic Development Services
We deliver cutting-edge diagnostic technologies to accelerate the discovery and validation of novel renal biomarkers, enabling earlier detection and precise monitoring of CKD progression.
Therapeutic Development Services
At Protheragen, we drive the identification and optimization of innovative drug candidates to target key molecular pathways driving renal inflammation and fibrosis.
Disease Model Development Services
Protheragen engineers highly reproducible in vitro and in vivo biological platforms that accurately replicate the pathophysiological hallmarks and progressive functional decline of human CKD.
Preclinical Research Services
Leveraging extensive expertise in renal disease research, we provide comprehensive pharmacology and safety evaluations to deliver high-quality data packages required for IND submissions of novel renoprotective therapies.
- Pharmacology Research
- Pharmacokinetics (PK) Studies
- Pharmacodynamics (PD) Evaluation
- Safety Toxicology Studies
Case Study 01-Mouse Model of 5/6 Nephrectomy
This case study evaluates a non-immunological chronic kidney disease (CKD) model established in C57BL/6 mice via 5/6 surgical nephrectomy, designed to simulate human progressive renal failure triggered by reduced nephron mass and glomerular hyperfiltration. Following surgical induction, the model group exhibited significant body weight loss, elevated serum urea and creatinine, and upregulated renal α-SMA/Col1a1 expression compared to controls, successfully confirming the establishment of a robust CKD phenotype accompanied by severe renal fibrosis.
Fig 1. 5/6 nephrectomy-induced CKD model in C57BL/6 mice: (A) Body weight; (B) Serum UREA; (C) Serum CRE; (D) Relative expression of renal α-SMA mRNA; (E) Relative expression of renal Col1a1 mRNA.
Case Study 02-Rat Model of 5/6 Nephrectomy
Protheragen successfully developed a robust 5/6 nephrectomy model in Sprague-Dawley (SD) rats to evaluate progressive chronic kidney disease (CKD) and validate potential renoprotective therapies. The study highlights a clear three-arm design comparing a Sham group (normal baseline control), a Model group (untreated 5/6 nephrectomy representing natural CKD progression), and an Empagliflozin group (therapeutic intervention group). Key evaluation endpoints measured to track functional decline and therapeutic efficacy included body weight, 24-hour urine volume, serum biochemical markers (CREA, BUN, TP, ALB, and UA), and 24-hour urinary excretion profiles (GLU and Na).
Fig 2. Experimental timeline for efficacy evaluation of Empagliflozin in a rat 5/6 nephrectomy model.
Compared with the Sham group, Model rats exhibited significantly elevated serum CREA/BUN and decreased levels of TP, ALB, and UA, successfully confirming CKD induction; notably, Empagliflozin treatment markedly reduced CREA, increased BUN, and restored TP, ALB, and UA levels toward normal baselines, demonstrating substantial renoprotective and metabolic regulatory effects. These findings demonstrate that the rat model of 5/6 nephrectomy serves as a reliable and sensitive translational platform for evaluating therapeutic candidates and elucidating target pathways in progressive chronic kidney disease.
Fig 3. Comparisons of serum biochemical indicators among Sham, Model, and Empagliflozin groups at different time points. (A) Blood creatinine (CREA), (B) blood urea nitrogen (BUN), (C) total protein (TP), (D) albumin (ALB), and (E) uric acid (UA). & P<0.05 vs. Sham; # P<0.05 vs. Model.
Case Study 03-Rabbit Model of 5/6 Nephrectomy
The 5/6 nephrectomy model in adult male New Zealand white rabbits was successfully established by Protheragen using a two-stage surgical approach—combining left kidney bipolar electrocoagulation with subsequent right nephrectomy—offering an ideal translational platform with larger renal anatomy, reduced peri-operative mortality, and capacity for longitudinal blood sampling.
Fig 4. Schematic experimental schedule of rabbit 5/6 nephrectomy CKD model.
To evaluate the physiological and biochemical impact of partial renal resection, general systemic characteristics were compared between two experimental cohorts: the Sham-operated group (Control), in which rabbits underwent laparotomy and simple kidney mobilization without nephrectomy, and the 5/6 nephrectomized group (CKD), which received a two-stage 5/6 nephrectomy to simulate the natural progression of chronic kidney disease. Key outcomes of this study include:
- Renal Insufficiency: CKD rabbits developed severe renal insufficiency, evidenced by a significant 58% reduction in median glomerular filtration rate (GFR) compared with the control group (P <0.001).
- Lipid Peroxidation: Plasma malondialdehyde (MDA) concentrations in CKD rabbits exhibited a tenfold increase relative to controls (P <0.001), indicating substantially elevated systemic lipid peroxidation.
- Antioxidant Capacity: CKD rabbits demonstrated a significant 15% reduction in median plasma antioxidant activity (AOA) compared with the sham-operated group (P <0.05).
Table 1. General characteristics of sham-operated (control) and 5/6 nephrectomized rabbits.
|
Characteristics |
Control (N=9) |
CKD (N=8) |
P Value |
|---|---|---|---|
|
Biometry |
|||
Body weight (kg) |
3.5 (3.2–3.9) |
3.1 (3.0–3.3) |
0.04 |
Body weight gain (kg) |
1.0 (0.9–1.2) |
0.7 (0.6–0.8) |
0.001 |
Kidney weight (g) |
19 (16–22) |
14 (12–16) |
0.008 |
Kidney weight (g/kg body wt) |
5 (4–7) |
5 (4–5) |
0.21 |
|
Biologic Features |
|||
Urea (mmol/L) |
6.8 (5.6–8.4) |
12.8 (12.6–19.2) |
<0.001 |
Creatinine (μmol/L) |
57 (52–75) |
193 (154–270) |
<0.001 |
Bicarbonate (mmol/L) |
20.1 (16.8–24.0) |
21.0 (14.6–22.7) |
0.7 |
Glucose (mmol/L) |
5.6 (4.8–6.9) |
7.4 (7.1–8.1) |
0.04 |
Total cholesterol (mg/dl) |
47 (37–68) |
109 (73–198) |
<0.001 |
HDL cholesterol (mg/dl) |
29 (18–37) |
56 (35–85) |
0.04 |
HDL-C/TC ratio |
0.66 (0.33–0.85) |
0.49 (0.35–0.53) |
0.27 |
Triacylglycerols (mg/dl) |
270 (228–677) |
316 (165–719) |
0.84 |
Protidemia (g/L) |
59 (48–69) |
39 (32–49) |
0.02 |
Proteinuria (g/mmol creatinine) |
617 (60–1287) |
19 (9–56) |
0.2 |
|
Lohexol Clearance |
|||
GFR (ml/min per kg) |
4.3 (4.1–4.8) |
2.2 (1.8–2.5) |
0.008 |
|
Oxidative Stress Markers (Plasma) |
|||
MDA (μmol/L) |
0.8 (0.5–1.2) |
2.3 (1.2–3.0) |
0.009 |
AOA (mmol/L) |
1.0 (0.8–1.1) |
0.8 (0.7–0.9) |
0.02 |
Why Choose Us?
- Deep Scientific & Surgical Expertise: Driven by multidisciplinary teams and strategic partnerships with clinical transplant surgeons, bringing clinical-grade microsurgical precision to experimental research.
- End-to-End Preclinical Services: Delivering fully integrated solutions in-house, spanning custom model establishment, therapeutic dosing, and in-depth biomarker evaluations to accelerate your drug discovery journey.
- Comprehensive Translational Disease Models: Access to a broad spectrum of highly characterizable CKD platforms across multiple species—including mice, rats, and rabbits—enabling seamless physiological, biochemical, and histopathological translation to human disease.
- Bespoke Customization & Rigorous Quality: Fully customizable study designs aligned with specific client pipeline needs, executed within AAALAC-compliant, state-of-the-art facilities ensuring high reproducibility and translational relevance.
Contact Us
An exceptional, validated preclinical model serves as the vital foundation for accelerating drug discovery in chronic kidney disease (CKD). Protheragen’s established 5/6 nephrectomy model platform—spanning mice, rats, and rabbits—coupled with our end-to-end surgical, biochemical, histopathological, and translational research capabilities, offers a robust and dependable partner for validating novel renoprotective, anti-fibrotic, and metabolic therapies. For detailed model characterization data, custom study design proposals, or to discuss your specific CKD research objectives, please contact our scientific team today.
Resource Download Request
Please complete the form to download the requested resources.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.